Navigation Links
Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2011 Financial Results and Provides Pipeline Update
Date:2/23/2012

initiated a phase I clinical study of IDX719, its NS5A inhibitor candidate. The first part of the study is evaluating the safety, pharmacokinetics and food effect of IDX719 in 48 healthy volunteers at single doses ranging from 5 to 100 mg. Dosing up to 50 mg has been completed in healthy volunteers and to date IDX719 has been well tolerated. A cohort of eight HCV genotype 1-infected patients received single doses of IDX719 of either 1, 5, 10 or 25 mg (2 patients per dose). Mean maximal viral load reductions were 1.9 log(10), 2.6 log(10), 3.3 log(10) and 3.7 log(10), respectively. A 3-day proof-of-concept segment of the study in treatment-naive genotype 1 HCV-infected patients is expected to begin in the second quarter of 2012 with additional cohorts of genotype 2, 3, or 4 HCV-infected patients to be added during the study.

Nucleotide Discovery ProgramIn January 2012, Idenix selected two nucleotide inhibitors, IDX19368 and IDX19370, as potential clinical candidates from its novel nucleotide prodrug discovery program. IDX19368 has demonstrated strong potency in preclinical studies and as a result the Company has chosen IDX19368 as its lead candidate and expects to submit an investigational new drug application (IND) for IDX19368 in mid-2012. The Company continues to identify new promising compounds and evaluate multiple candidates for further development from this discovery program.

"Our focus for 2012 will be to build on the progress we made last year through the continued advancement of our pipeline of novel HCV drug candidates," said Ron Renaud, Idenix's President and Chief Executive Officer. "Now that the partial clinical hold has been removed for IDX184, we will be able to explore the full potential of this promising nucleotide polymerase inhibitor in combination with other DAAs in a broad phase IIb program. The early results are promising for IDX719, our NS5A inhibitor, in HCV patients and we look forward to completing the phase I clinical tria
'/>"/>

SOURCE Idenix Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8

Related medicine technology :

1. Idenix Pharmaceuticals Provides Update on Hepatitis C Pipeline at JP Morgan Healthcare Conference
2. Idenix Pharmaceuticals Presents Positive Preclinical Data on HCV Programs at The Annual Meeting of The European Association for the Study of the Liver (EASL)
3. Idenix Pharmaceuticals Reports First Quarter 2008 Financial Results
4. Idenix Pharmaceuticals Advances HCV Discovery Program to Clinic
5. Idenix Pharmaceuticals Announces Completion of Proof-of-Concept Study for IDX899 in Treatment-Naive HIV-Infected Patients
6. Idenix Pharmaceuticals Initiates Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
7. Idenix Pharmaceuticals and GlaxoSmithKline Sign Worldwide License Agreement for IDX899, a Novel NNRTI for the Treatment of HIV
8. Idenix Pharmaceuticals Successfully Completes Proof-of-Concept Study of IDX184 for the Treatment of Hepatitis C Virus (HCV)
9. Idenix Pharmaceuticals Reports Fourth Quarter and Year End 2009 Financial Results
10. Idenix Pharmaceuticals to Present at Two Upcoming Investor Conferences
11. Idenix Announces Data Presentations at the 61st Annual Meeting of the American Association for the Study of Liver Diseases (AASLD)
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/17/2015)... , April 17, 2015 Today, ... honored 13 employees from 12 biopharmaceutical companies as ... efforts in policy advocacy and community service. ... Health Champion Awards were created by the biopharmaceutical ... excelled in their careers, but have also shown ...
(Date:4/17/2015)... , Apr. 16, 2015 Research and Markets ... the "Corporate Reputation of Pharma in 2014 - ... Edition" report to their offering. For ... opinions on the corporate reputation of the pharmaceutical industry ... health with the views of patient organisations representing all ...
(Date:4/16/2015)... , April 16, 2015 Vanda Pharmaceuticals ... focused on the development and commercialization of products for ... it will release results for the first quarter of ... closes. The Company will host a ... 6, 2015, during which Vanda management will discuss the ...
Breaking Medicine Technology:PhRMA Applauds 2015 We Work For Health Champion Award Winners 2PhRMA Applauds 2015 We Work For Health Champion Award Winners 3Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 2Corporate Reputation of Pharma in 2014 - The Perspective of Mental Health Patient Groups - 1st Edition 3Vanda Pharmaceuticals to Announce First Quarter 2015 Financial Results on May 6, 2015 2
... Dec. 22, 2010 Haemonetics Corporation (NYSE: ... Chief Executive Officer, will present at the J.P. Morgan ... 2011 at 1:30 pm Pacific time.  The ... at http://jpmorgan.metameetings.com/webcasts/healthcare11/directlink?ticker=HAE .  The webcast ...
... ISTA Pharmaceuticals, Inc. (Nasdaq: ISTA ), today ... update webcast/conference call after the market closes on January ... Vicente Anido, Jr., Ph.D., and Chief Financial Officer and ... 2011 guidance, give a commercial and new product pipeline ...
Cached Medicine Technology:ISTA Pharmaceuticals Announces 2011 Guidance and Pipeline Update Webcast/Conference Call on January 5, 2011 2
(Date:4/18/2015)... 18, 2015 "I wanted to ... create a healthful juice that contained essential vitamins, ... Md. "It increases my energy, improves skin elasticity ... He developed Tapp's Juice to contain fruits, vegetables ... prevent physical and mental fatigue. It features a ...
(Date:4/18/2015)... has released a new blog post explaining how to ... , Drivers can find accurate information about various auto ... website can help drivers compare the newest and best ... whole process is designed to be convenient, free and ... quotes is advantageous because it allows clients to find ...
(Date:4/18/2015)... (PRWEB) April 18, 2015 More than ... sale now at TheCelebrityDresses.com, the #1 online store carrying ... ongoing many girls have got their perfect dresses for ... the celebrity fashion prom dresses at TheCelebrityDresses.com would be ... designed more than 2000 prom dresses inspired by the ...
(Date:4/18/2015)... 2015 PHOENIX, ARIZONA – In March, ... 11 other secure destruction professionals across the United States, ... He will now display “CSDS” as a professional title ... the National Association of Information Destruction 2015 Annual Conference ... Texas. Of the 20 people who took the exam, ...
(Date:4/17/2015)... 2015 Rosetta Radiology is proud to ... their list of diagnostic imaging services. This solidifies them ... the Upper East Side of Manhattan. , The new ... The addition of PET-CT, combined with Rosetta’s state of ... to work with patients through several stages of the ...
Breaking Medicine News(10 mins):Health News:Auto Insurance Quotes Can Provide Accurate Results! 2Health News:Prom Dresses 2015 on Sale at TheCelebrityDresses.com 2
... American Society,for Therapeutic Radiology and Oncology is pleased to ... Oriental Republic of,Uruguay, will present a special guest lecture ... 1 in Los Angeles. Dr. Vazquez, who,is a radiation ... speak October 30 at 9:00 a.m. at the Los ...
... but not all , WEDNESDAY, Oct. 17 (HealthDay News) -- ... pain. , That,s the conclusion of Israeli researchers who reviewed ... insoles to sham insoles or no treatment for back pain ... of 256 people that focused on the use of insoles ...
... Help Advance Research-, MISSION VIEJO, Calif., Oct. ... for its innovative genomic search,technology, SLIM Search(TM), Inc. ... The SLIM Search genomic search tool delivers greater ... 1.3 includes the following features: * ...
... 17 After completing its review of safety,and ... Board (DSMB) has recommended that the pivotal Phase ... Edema) Study,continue under the current protocol, without change. ... for the treatment of diabetic macular edema (DME). ...
... Oct. 17 IRIDEX,Corporation (Nasdaq: IRIX ) announced ... and Chief Executive Officer, and as a member of,the ... The Board of,Directors has appointed Theodore A. Boutacoff, who ... Directors, to serve as the Company,s President,and Chief Executive ...
... - For the Nine Months (to 31 August) a 46% Sales ... in EBIT to EUR34.8m (EUR6.2m) - Marked Improvement in Adjusted ... Fall in Interest Charges Since the IPO - CEO Dr. ... In the first nine months of its financial year (to ...
Cached Medicine News:Health News:President of Uruguay to Speak at ASTRO Annual Meeting 2Health News:Release 1.3 of SLIM Search Now Available 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 2Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 3Health News:DSMB Supports Continuation of the Phase 3 Clinical Trial of Medidur(TM) FA for the Treatment of DME 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 2Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 3Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 4Health News:Growth Trend for Gerresheimer Continues Unabated - Debt Reduction 5
... cool-running, energy efficient LEDs (Light Emitting Diodes) ... see without affecting the darkened refracting environment. ... free so you'll never need to change ... a limited lifetime warranty, the best in ...
... The Reichert CT200 Tonometer ... the XCEL 250 and XCEL ... also compatible with other Zeiss-style ... mounted on the top of ...
10 (mm) smooth platform; Serrated handle in stainless steel....
Compatible with the Volcano Therapeutics Trak Back II Disposable Catheter Pullback Device,and the Volcano Therapeutics In-Vision Imaging System....
Medicine Products: